Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. The company's mission is to protect and save lives by developing, manufacturing, and delivering solutions that address accidental, intentional, and naturally occurring public health threats. It focuses on providing critical medical countermeasures and specialty products for various public health challenges.

Emergent BioSolutions offers a diverse portfolio of products, including NARCAN Nasal Spray for opioid overdose emergencies, BioThrax and CYFENDUS for anthrax, ACAM2000 and TEMBEXA for smallpox and mpox, and Ebanga for Ebola. The company also provides vaccines for infectious diseases such as cholera (Vaxchora) and typhoid fever (Vivotif). Beyond its proprietary products, Emergent BioSolutions provides Contract Development and Manufacturing Organization (CDMO) services to other biopharmaceutical companies. Its primary customers for medical countermeasures are government agencies, particularly in the U.S. and allied nations, while commercial and public interest channels are targeted for products like NARCAN.

Joseph C. Papa serves as the President and CEO of Emergent BioSolutions. In the first quarter of 2026, the company reported revenues of $156.1 million and a net income of $6.8 million. Recent strategic initiatives include securing new manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics, and refinancing its term loan to enhance financial flexibility. Emergent BioSolutions has also expanded its efforts in opioid overdose preparedness, partnering with British Columbia to supply NARCAN Nasal Spray for their Take-Home Naloxone Program and launching new carrying cases and multipacks for the product. The company maintains a leading market position in specialized biopharmaceuticals, particularly in medical countermeasures and naloxone, supported by strong relationships with government entities.

Latest updates

Emergent BioSolutions Revenue Declines as Government Contracts Wane

Event summary

  • Emergent BioSolutions reported Q1 2026 revenues of $156.1 million, below the high end of its guidance range.
  • Net income decreased significantly to $6.8 million, a 90% drop year-over-year, resulting in a 4% net income margin.
  • Revenue from Anthrax MCM products fell by 55% and Smallpox MCM products by 40% year-over-year, primarily due to timing and reduced government contracts.
  • Emergent secured a manufacturing partnership with Substipharm Biologics, including exclusive U.S. distribution rights for its Japanese Encephalitis vaccine post-FDA approval.

The big picture

Emergent BioSolutions' Q1 results highlight the challenges facing biodefense companies heavily reliant on government contracts. The decline in revenue underscores the cyclical nature of these contracts and the need for diversification. The partnership with Substipharm represents a strategic shift towards broader commercialization, but the company's long-term success will depend on its ability to reduce its dependence on government funding and improve operational efficiency amidst a shifting geopolitical landscape.

What we're watching

Contract Dependence
The company's reliance on U.S. and international government contracts remains a significant vulnerability, as evidenced by the substantial revenue declines in Anthrax and Smallpox MCM segments. Future performance hinges on securing new contracts and diversifying revenue streams.
Margin Pressure
Declining sales volumes and unfavorable product mixes are compressing margins, necessitating a focus on cost optimization and potentially pricing adjustments to maintain profitability.
Distribution Expansion
The exclusive U.S. distribution rights for Substipharm’s Japanese Encephalitis vaccine represent a potential growth driver, but its success will depend on navigating FDA approval timelines and establishing a robust commercial infrastructure.

Singapore Approves Expanded ACAM2000 Use, Bolstering Emergent's Portfolio

Event summary

  • Singapore’s Health Sciences Authority (HSA) approved an expanded indication for Emergent BioSolutions’ ACAM2000 vaccine to include prevention of mpox disease in high-risk adults.
  • The approval is based on existing safety data and animal study results demonstrating vaccine efficacy against mpox virus.
  • ACAM2000 was initially approved by the HSA in 2009 for smallpox prevention.
  • The vaccine is administered via a bifurcated needle and carries significant safety risks, including myocarditis and severe skin infections (see FDA safety information).

The big picture

This approval represents a strategic win for Emergent, expanding the utility of a core product and reinforcing its position in the biodefense market. However, the vaccine's inherent safety risks and the availability of alternatives will likely constrain market penetration. The approval also highlights the ongoing need for preparedness against emerging infectious diseases, a trend likely to drive continued government investment in countermeasures.

What we're watching

Market Adoption
The speed of ACAM2000 adoption in Singapore will depend on public health messaging and the availability of alternative mpox vaccines, potentially limiting revenue upside.
Liability Risk
Given the vaccine's known safety profile, Emergent will need to proactively manage liability exposure and ensure robust adverse event reporting systems are in place.
Geographic Expansion
Further regulatory approvals in other high-risk regions will be crucial for realizing the full potential of ACAM2000 and driving broader portfolio growth.

Emergent BioSolutions Secures $50M Manufacturing Deal for SAB Biotherapeutics' Diabetes Candidate

Event summary

  • Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million.
  • $36 million of the contract is contingent on future regulatory approval and downstream milestones for SAB-142, SAB Biotherapeutics’ lead T1D candidate.
  • The agreement covers process development, manufacturing, and analytical method transfer, utilizing Emergent’s Winnipeg facility.
  • SAB-142 is currently in a Phase 2b clinical trial (SAFEGUARD) for newly diagnosed Stage 3 T1D patients.

The big picture

This agreement underscores the growing trend of smaller biopharmaceutical companies outsourcing manufacturing to specialized contract development and manufacturing organizations (CDMOs) like Emergent, particularly for complex biologics. The $50 million deal provides Emergent with a significant revenue stream, but its success is heavily tied to the clinical progress of SAB-142 and the broader T1D treatment landscape, which remains a significant unmet medical need.

What we're watching

Clinical Progress
The success of SAB-142’s Phase 2b trial, SAFEGUARD, will be critical in determining whether Emergent receives the full $50 million contract value and signals broader commercial viability.
Capacity Utilization
How Emergent’s Winnipeg facility balances this new contract with its existing commitments, particularly given its focus on plasma-derived and complex biologics, will influence its overall margins.
Regulatory Risk
The contingent nature of $36 million of the deal highlights the regulatory risk inherent in biopharmaceutical development, and any setbacks for SAB-142 could impact Emergent’s revenue stream.

Emergent BioSolutions Leverages Athlete Partnership to Boost NARCAN® Awareness in Canada

Event summary

  • Emergent BioSolutions partnered with professional baseball player Davis Schneider to raise awareness of NARCAN® Nasal Spray among Canadians.
  • Schneider is sharing his family’s story of opioid loss as part of Emergent’s Opioid Crisis Impact Map.
  • Canada is experiencing an opioid poisoning epidemic, with approximately 17 lives lost daily.
  • Emergent has distributed over 100 million NARCAN® Nasal Spray doses in Canada and the U.S. since 2018.
  • NARCAN® Nasal Spray is currently available at no cost in several Canadian provinces and territories through public health programs.

The big picture

Emergent BioSolutions is leveraging a high-profile athlete partnership to address a critical public health crisis in Canada. The opioid epidemic represents a significant market opportunity for overdose reversal medications, but also carries reputational and regulatory risks. This initiative underscores the growing trend of pharmaceutical companies engaging in social impact marketing to build brand trust and navigate complex ethical considerations.

What we're watching

Public Perception
The effectiveness of the partnership with Davis Schneider in reducing the stigma surrounding opioid use and increasing NARCAN® adoption will be a key indicator of Emergent's broader public health strategy.
Government Funding
Continued reliance on provincial and territorial programs for NARCAN® distribution creates exposure to shifts in government priorities and funding allocations, potentially impacting Emergent’s sales.
Competitive Landscape
The emergence of alternative opioid overdose reversal treatments could erode NARCAN®’s market share and necessitate further promotional efforts from Emergent.

Emergent BioSolutions Secures Vaccine Manufacturing, Distribution Deal with Substipharm

Event summary

  • Emergent BioSolutions and Substipharm Biologics have signed a $34.5 million Manufacturing Services Agreement.
  • Emergent’s Canton facility will manufacture the drug substance for Substipharm’s Japanese Encephalitis (JE) vaccine, IMOJEV®.
  • Emergent gains exclusive distribution rights to the vaccine for the U.S. government pending FDA approval.
  • The FDA classified Emergent Canton’s February 2026 inspection as “No Action Indicated,” signaling compliance with GMP standards.
  • IMOJEV® is currently used in several Asian countries but not approved for use in the U.S.

The big picture

This partnership represents a strategic move by Emergent to bolster its U.S. government contracts and onshore critical medicine production, aligning with recent policy initiatives. Substipharm, a private French healthcare group, is leveraging Emergent’s established manufacturing capabilities and regulatory expertise to enter the U.S. market with its Japanese Encephalitis vaccine. The deal highlights the increasing demand for specialized vaccine manufacturing capacity, particularly for diseases prevalent in Asia.

What we're watching

Regulatory Approval
The timeline for FDA approval of IMOJEV® will be a key indicator of the partnership's success and Emergent's ability to expand its product portfolio.
Execution Risk
How effectively Emergent integrates Substipharm’s manufacturing process at the Canton facility will determine the long-term viability and profitability of the agreement.
Government Demand
The U.S. government’s ongoing preparedness needs and willingness to procure IMOJEV® will dictate the scale of Emergent’s distribution revenue.
CID: 2110